Indian Vaccine Regulatory System
The World Health Organization (WHO) has given the Indian vaccine regulatory structure the highest possible rating of 4 on a majority of parameters. NRAs are defined by the WHO as “national regulatory agencies responsible for ensuring that products released for public distribution (normally pharmaceuticals and biological products, such as vaccines) are evaluated properly and meet international standards of quality and safety”.
Indian Context
In India’s case, the NRA, as defined by the WHO, comprises the Central Drugs Standard Control Organisation (CDSCO), which has regulatory control over the import of drugs, approval of new drugs and clinical trials; the State Drug Regulatory Authorities; the Pharmacovigilance Programme of India (PvPI), the country’s national drug safety programme; and the Adverse Events Following Immunization (AEFI) structures at the central and state levels.
Parameters
The Indian NRA was assessed on nine functions. These were,
# Quality of the national regulatory system
# Registration and marketing authorisation
# Vigilance
# Laboratory access and testing
# Regulatory inspection
# Clinical trial oversight
# NRA lot release
# Licensing premises, and
#Market surveillance and control.
Significance of 4 rating
In simple terms, it means that India has been classified as a stringent regulator of vaccines alongside developed countries such as the US, Japan and EU member states. A fully functional NRA is a prerequisite for WHO prequalification of vaccines. One of the requirements to become eligible and retain prequalification status is to have the National Regulatory Authority (NRA) assessed as functional against WHO-published NRA indicators.
The WHO Prequalification Programme facilitates access to vaccines that meet unified standards of quality, safety and efficacy, as well as programme needs. Vaccine manufacturers can only apply for WHO vaccine prequalification if the NRA meets the standards of the WHO-published NRA indicators, i.e., the WHO Global Benchmarking Tool on the functional regulatory system for vaccines.
Health economy in India
The total value of vaccines manufactured by Indian companies is estimated to be in the range of $ 900 million. About 65%-70% is exported — India is a major player in the vaccine supply chain to agencies such as UNICEF, the WHO and the Pan American Health Organisation (PAHO).
Road Ahead
It will make it easier for pharmaceutical companies to enter international markets. This will “give an impetus to the “Make in India” mantra of the Hon’ble Prime Minister of India”.

